Overview

We are a leading global provider of Recombinant Antibody Production Services, offering end-to-end solutions for the expression, purification, and characterization of custom antibody molecules. In an era defined by precision biologics, our platform enables the reliable, reproducible, and scalable manufacture of monoclonal antibodies, antibody fragments (scFv, Fab, VHH), bispecifics, and antibody-drug conjugates (ADCs) entirely in vitro. By bypassing traditional hybridoma or animal immunization systems, we provide a faster, more controlled, and ethically aligned path from antibody sequence to purified protein. Leveraging state-of-the-art expression systems—including mammalian (HEK293, CHO), microbial (E. coli, yeast), and cell-free platforms—our team of molecular biologists, cell culture specialists, and protein chemists delivers high-purity, functional antibodies tailored to your exact specifications for applications ranging from basic research to preclinical and clinical development.

☞Why Choose Our Recombinant Antibody Service?

Choosing our service provides a decisive strategic and operational advantage for projects where consistency, scalability, and complete control over the antibody sequence and format are paramount.

• Expertise in Multiple Expression Platforms: We are not limited to a single system. We will recommend and expertly execute the optimal platform for your project—mammalian for complex glycosylation and high-fidelity folding, microbial for rapid, cost-effective production of fragments, or cell-free for toxic proteins or high-throughput screening—ensuring the best balance of yield, quality, and timeline.

• Seamless Integration with Discovery Pipelines: We are the ideal partner following phage display, single B cell, or other discovery campaigns. We efficiently take your identified VH/VL or VHH sequences, perform codon optimization, and transition them into a production-ready format, bridging the gap between discovery and development.

• Focus on Quality by Design: Our processes are built from the ground up to ensure product quality. This includes rigorous vector design, stable cell line development (for CHO), comprehensive analytics, and adherence to quality management principles, providing you with a product that is characterized, consistent, and suitable for sensitive downstream applications.

• Unmatched Scalability & Reproducibility: From milligram quantities for assay development to gram-scale for in vivo studies and beyond, we offer a scalable path. Recombinant production guarantees batch-to-batch consistency that is often challenging with traditional methods, de-risking your long-term project supply.

• Full Customization & Engineering Support: We specialize in producing not just standard IgGs but also engineered formats. Our team can assist with and execute projects involving Fc silencing mutations, site-specific conjugation handles (e.g., for ADC payloads), humanization, affinity maturation, and the assembly of bispecific or multispecific antibodies.

• Dedicated Project Management: You are assigned a dedicated scientist who manages your project from gene synthesis through final purification, providing regular updates, troubleshooting support, and delivering a comprehensive data package.

☞What is a Recombinant Antibody?

A recombinant antibody is an immunoglobulin molecule that is produced using recombinant DNA technology. Unlike monoclonal antibodies derived from hybridomas (which are biological cell lines), recombinant antibodies are generated by cloning the antibody gene sequences into an expression vector, which is then introduced into a host cell or organism to produce the protein.

The fundamental process involves:

• Genetic Blueprint: Starting with the known DNA sequences encoding the antibody's variable (VH and VL) and constant regions.

• Vector Construction: These genes are assembled and inserted into a plasmid or viral vector, which contains regulatory elements (promoters, enhancers) to drive expression in the chosen host cell.

• Host Cell Expression: The vector is delivered into a host cell system (e.g., CHO, HEK293, E. coli). The cell's machinery reads the engineered DNA and synthesizes the antibody protein.

• Purification: The antibody is harvested from the culture medium (or cell lysate) and purified to homogeneity using chromatographic techniques.

This method completely decouples antibody production from any biological immune system, allowing for the rational design and engineering of antibody properties at the genetic level.

☞Advantages of Recombinant Antibodies

The recombinant approach offers significant benefits over traditional antibody generation methods:

• Defined Sequence & Intellectual Property (IP): The exact genetic sequence is known and controlled, creating a clear and strong IP position. There is no risk of hybridoma drift or loss.

• Superior Consistency & Reproducibility: Production is independent of living animals or unstable cell fusions. Every batch is produced from the same genetic template in a controlled bioreactor environment, ensuring identical product characteristics.

• Animal-Free Production: Eliminates the ethical concerns and variability associated with animal immunization and ascites production. Aligns with the 3Rs principles (Replacement, Reduction, Refinement) and is favored by regulatory bodies.

• Speed & Scalability: Once the gene is cloned, producing a new batch is faster than re-thawing and expanding a hybridoma. The process is inherently scalable from shaker flasks to large-scale bioreactors.

• Unlimited Format Engineering: The modular nature of antibody genes allows for easy engineering. We can produce full-length IgGs, minimal binding fragments (scFv, Fab, VHH), bispecific formats, Fc-fusion proteins, or antibodies with site-specific tags for conjugation.

• Optimized Properties: The sequence can be engineered for improved characteristics, such as enhanced stability, reduced immunogenicity (humanization), altered effector function (Fc engineering), or tuned pharmacokinetics.

• Access to "Undruggable" Targets: Antibodies against targets that are toxic, highly conserved, or poorly immunogenic in animals can be discovered in vitro (e.g., via phage display) and produced recombinantly without ever needing an immune response.

☞Recombinant Antibody Production Process

Our production process is a systematic, multi-stage journey from digital sequence to purified, vialed protein.

 Phase 1: Gene Synthesis, Optimization & Vector Construction 

• Sequence Preparation: Your antibody variable and constant region sequences are received.

• Codon Optimization & Gene Synthesis: We optimize the DNA sequence for maximum expression in the chosen host organism (e.g., humanizing codons for CHO cells) and synthesize the full gene.

• Vector Assembly: The synthesized gene is cloned into an expression vector tailored for the host system (e.g., a mammalian vector with a strong promoter like CMV and a selection marker like glutamine synthetase for CHO).

 Phase 2: Host Cell Transfection & Selection 

• Transient Transfection (Rapid): For mammalian systems like HEK293, the plasmid is directly introduced into cells to produce antibody over 7-14 days. Ideal for rapid production of mg to gram quantities for research.

• Stable Cell Line Development (Scalable): For CHO cells, the vector is integrated into the host genome. Cells are subjected to selective pressure, and high-producing single-cell clones are isolated, screened, and expanded to create a Master Cell Bank (MCB). This is the gold standard for large-scale, reproducible GMP manufacturing.

 Phase 3: Upstream Process – Cell Culture & Expression 

• Process Development: We optimize culture conditions (media, feed strategy, pH, dissolved oxygen, temperature) in bench-top bioreactors to maximize cell density and antibody productivity (titer).

• Scale-Up Production: The optimized process is scaled to the required volume in stirred-tank bioreactors, where environmental parameters are tightly controlled to ensure consistent, high-yield production.

 Phase 4: Downstream Process – Harvest, Purification & Polishing 

• Harvest & Clarification: Cells are removed via centrifugation and depth filtration to obtain a clarified cell culture supernatant containing the antibody.

• Capture Chromatography: Typically, Protein A affinity chromatography (for IgG) is used for high-efficiency capture and initial purification.

• Polishing Chromatography: Additional steps, such as cation exchange (CEX) and anion exchange (AEX) chromatography, are employed to remove impurities like host cell proteins (HCPs), DNA, aggregates, and leached Protein A.

• Viral Clearance (if required): For processes destined for in vivo use, dedicated viral inactivation (low pH hold) and removal (nanofiltration) steps are integrated.

 Phase 5: Formulation, Analytics & Quality Control 

• Ultrafiltration/Diafiltration (UF/DF): The purified antibody is concentrated and exchanged into its final formulation buffer (e.g., PBS, histidine-sucrose).

• Sterile Filtration: The product is passed through a 0.22 µm filter.

• Comprehensive Analytics: The final product undergoes rigorous QC, including concentration (A280), purity (SDS-PAGE, SEC-HPLC for aggregates), identity (mass spectrometry), potency (binding ELISA/SPR), and safety tests (endotoxin, sterility).

☞Our Service Workflow

Our client-centric workflow is designed for clarity, collaboration, and successful project execution.

Step 1: Project Consultation & Strategy Design

We discuss your antibody sequence, format, quantity, quality requirements, and timeline. We then recommend the optimal expression platform and provide a detailed project plan and quotation.

Step 2: Gene & Vector Preparation

Upon project initiation, we proceed with gene synthesis, codon optimization, and vector construction. We provide sequence confirmation documentation.

Step 3: Expression & Production

Our upstream team performs transfection and cell culture. For stable cell line projects, we provide clone screening data and establish the MCB. You receive regular updates on titers and progress.

Step 4: Purification & Process Analytics

The downstream team harvests and purifies the antibody. In-process analytics are performed to monitor yield and purity at each step.

Step 5: Full Characterization & QC

The final, formulated product undergoes our full analytical panel. We compile a draft Certificate of Analysis (CoA) and a detailed project report for your review.

Step 6: Final Delivery & Support

Upon your approval, we ship the purified recombinant antibody under appropriate conditions, along with the final CoA and all project documentation. We offer post-delivery technical support.

 Our Service Process Flowchart: 

Partner with us to leverage the power, precision, and scalability of recombinant antibody technology. Contact our team today to initiate your production project and obtain a reliable, high-quality antibody tailored to your advanced research or development needs.